Thursday, April 23, 2009

Isentress’s Prevention Potential, via

The integrase inhibitor Isentress (raltegravir), when taken by either HIV-negative or HIV-positive people, might be able to prevent HIV transmission, according to a presentation at the International Clinical Pharmacology Workshop in Amsterdam.

Though Viread (tenofovir) and Truvada (tenofovir plus emtricitabine) are the leading antiretroviral (ARV) treatments being tested for use in HIV-negative people to prevent HIV infection, other ARVs are being considered for pre-exposure prophylaxis (PrEP). Researchers have also begun studying whether treating HIV-positive people, regardless of their CD4 count or medical need for ARV therapy, might help them reduce the risk of transmitting HIV to their HIV-negative partners.

Read the rest.


Anonymous said...

Isentress is the only drug that works for me. It's a shame I had to try everything else before I found it... could have saved many years of feeling terrible. When will research about this transmission prevention study be published?

Jim said...

Check out all info on PrEP trials here, on PrEP Watch:

Related Posts Plugin for WordPress, Blogger...